<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154842">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02080091</url>
  </required_header>
  <id_info>
    <org_study_id>M-01-13-003</org_study_id>
    <nct_id>NCT02080091</nct_id>
  </id_info>
  <brief_title>Observational Study to Assess the Effect of Iluvien® in DME Patients Insufficiently Responsive to Available Therapies</brief_title>
  <acronym>ILUMINATE</acronym>
  <official_title>ILUMINATE: An Open-Label, Non-Interventional Study of the Safety and Effect of Iluvien® (Fluocinolone Acetonide 190 Micrograms Intravitreal Implant in Applicator) in Patients With Chronic Diabetic Macular Edema (DME) Insufficiently Responsive to Available Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alimera Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alimera Sciences</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational study aims to assess the safety and effect of Iluvien® in DME patients
      considered insufficiently responsive to available therapies in a real life setting in
      Germany.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>24 Months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Observed and change from baseline visual acuity LogMAR scores will be summarized using descriptive statistics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with Adverse Events</measure>
    <time_frame>24 Months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retinal Center Subfield Thickness</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Observed and change from baseline SD-OCT values will be summarized using descriptive statistics.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Diabetic Macular Edema (DME)</condition>
  <arm_group>
    <arm_group_label>Chronic DME</arm_group_label>
    <description>Patients with vision impairment associated with chronic diabetic macular edema (DME)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with DME considered insufficiently responsive to available therapies in
        approximately 25 ophthalmology centers (private practice or hospital) across Germany
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients of both sexes that have signed informed consent after detailed
             information about the characteristics of the observation by the physician

          -  DME based on physician's clinical evaluation and demonstrated on fundus photographs
             and/or fluorescein angiograms and/or optical coherence tomography (OCT)

          -  Vision impairment associated with DME

          -  Prior treatment with available therapies for DME; and

          -  Patients considered by the physician insufficiently responsive to available therapies

        Exclusion Criteria:

          -  Patients with contraindications according to the current Summary of Product
             Characteristics (SPC)

          -  The presence of pre-existing glaucoma

          -  Active or suspected ocular or periocular infection

          -  The patient is hypersensitive to the active agent or to one of the excipients

          -  Elevated IOP

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Professor Helmut Hoeh, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dietrich-Bonhoeffer-Klinikum</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian Benkenstein, PhD</last_name>
    <phone>+49 (0)1525-6742-953</phone>
    <email>christian.benkenstein@quintiles.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Neubrandenburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Professor Helmut Hoeh, MD</last_name>
      <phone>+49 395-7753469</phone>
      <email>aug@dbknb.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 4, 2014</lastchanged_date>
  <firstreceived_date>March 3, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluocinolone Acetonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
